Arkolith/Insider Trading/SRRA/Form 4

Sinclair Andrew

DirectorSierra Oncology, Inc. (SRRA) · full profile →Form 4 · filed Jul 1, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
1 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2022Disposed to issuer(D)1.3M$55.00$72.3M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 1, 2022Disposed to issuer(D)871K$45.98$40.1M0
Jul 1, 2022Disposed to issuer(D)7K——0
Jul 1, 2022Disposed to issuer(D)6K——0
Jul 1, 2022Disposed to issuer(D)2K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-22-018397) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML